Paclitaxel (Taxol) in relapsed and refractory ovarian cancer: the UK and Eire experience
- 1 October 1995
- journal article
- clinical trial
- Published by Springer Nature in British Journal of Cancer
- Vol. 72 (4) , 1016-1019
- https://doi.org/10.1038/bjc.1995.453
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103.Journal of Clinical Oncology, 1993
- Second‐line chemotherapy for recurrent carcinoma of the ovaryCancer, 1993
- Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma.Journal of Clinical Oncology, 1992
- Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.Journal of Clinical Oncology, 1991
- Taxol: A Unique Antineoplastic Agent with Significant Activity in Advanced Ovarian Epithelial NeoplasmsAnnals of Internal Medicine, 1989
- Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trialsBritish Journal of Cancer, 1989
- Promotion of microtubule assembly in vitro by taxolNature, 1979